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Objectives. The purpose of this study was to determine the level
and functional effects of endogenous bradykinin in congestive
heart failure (CHF).
Background. There is experimental evidence that bradykinin is
increased in several cardiac disease states. However, it is un-
known whether plasma levels of bradykinin are elevated in CHF.
Further, the cardiac and vascular responses to bradykinin in CHF
are unclear.
Methods. The circulating levels of bradykinin and the effects of
endogenous bradykinin were assessed in eight instrumented,
conscious dogs both before and after pacing-induced CHF.
Results. Before CHF, the plasma bradykinin level was 53.1 6
12.4 pg/ml. Blocking endogenous bradykinin with HOE-140
(0.3 mg/kg), a specific bradykinin B2-receptor antagonist, pro-
duced no significant alterations in heart rate, left ventricular (LV)
end-systolic pressure (Pes), total systemic resistance (TSR), the
time constant of LV relaxation (tau) or the maximal rate of LV
filling (dV/dtmax). However, coronary blood flow was significantly
reduced (p < 0.05). LV contractile performance measured by the
slopes of pressure–volume relations was unaffected. After induc-
tion of CHF, the plasma bradykinin level increased to 234.2 6 19.4
pg/ml (p < 0.05). Blocking endogenous bradykinin with HOE-140
reduced coronary blood flow and produced significant increases in
Pes and TSR, prolonged tau, decreased dV/dtmax and elevated
minimal LV pressure and mean left atrial pressure. Furthermore,
the slopes of pressure–volume relations (p < 0.05) were de-
creased, indicating depressed contractility with HOE-140 after
CHF.
Conclusions. Before CHF, endogenous bradykinin results in
coronary dilation but has no effect on systemic arterial vasodila-
tion or cardiac performance. After CHF, endogenous bradykinin
is significantly increased and, acting through B2-receptors, pro-
duces coronary and arterial vasodilation and improves LV relax-
ation and contractile performance. Thus, endogenous bradykinin
may play an important role in preserving cardiovascular function
in CHF.
(J Am Coll Cardiol 1998;31:1679–86)
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There is neurohormonal activation in congestive heart failure
(CHF) (1,2). This stimulation of the renin–angiotensin system,
norepinephrine, vasopressin and endothelin may help acutely
compensate for impaired cardiac function. However, the long-
term activation of these systems has adverse consequences,
including vasoconstriction (1,3–6), sodium retention and car-
diac remodeling (7,8). In addition, angiotensin II may also
produce direct depression of left ventricular (LV) contraction
and relaxation in CHF (9). In contrast, activation of the
kallikrein–kinin system, if it occurs in CHF, may be beneficial.
Bradykinin reduces both systemic and coronary resistance
(10–13), has positive inotropic and lusitropic effects (14–16)
and is a cardioprotective agent that may decrease myocardial
oxygen consumption and ischemia (17,18). If bradykinin is
increased in CHF, it may help counteract some of the detri-
mental effects of sympathetic and renin–angiotensin system
activation. There is experimental evidence that bradykinin
(11,18–22) is increased in cardiac ischemia (23,24), myocardial
infarction (25,26), inflammation, hypotension (27) and shock
(28). However, it is unknown whether plasma levels of brady-
kinin are elevated in CHF. Further, the cardiac and vascular
responses to bradykinin have not been assessed in CHF.
Thus, we hypothesized that circulating bradykinin is in-
creased in CHF and has a beneficial effect on cardiac function.
We tested this hypothesis by measuring bradykinin levels and
determining the consequences of blocking the cardiovascular
effects of endogenous bradykinin in conscious dogs before and
after pacing-induced CHF.
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Methods
Instrumentation. This investigation conformed with the
“Guide for the Care and Use of Laboratory Animals,” pub-
lished by the National Institutes of Health (NIH publication
no. 86-25, revised 1985).
Eight healthy, adult, heart-worm negative, mongrel dogs
(weight 25 to 34 kg) were instrumented under anesthesia
induced with xylazine (2 mg/kg body weight intramuscularly)
and sodium thiopental (6 mg/kg intravenously) and maintained
with halothane (0.5% to 2%). They were intubated and
ventilated with oxygen-enriched room air to maintain an
arterial oxygen tension .100 mm Hg and pH between 7.38 and
7.42. A left lateral thoracotomy was performed aseptically.
Micromanometer pressure transducers (Konigsberg Instru-
ments) and polyvinyl catheters for transducer calibration (in-
ternal diameter 1.1 mm) were inserted into the LV and left
atrium (LA). Three pairs of ultrasonic crystals (5 MHz)
(Custom Transducers) were implanted in the endocardium of
the LV to measure the anterior-posterior, septal-lateral and
base-apex (long-axis) dimensions, using previously described
methods (29). Hydraulic occluded cuffs were placed around
the superior and inferior venae cavae. Two 54-cm sutureless
myocardial leads (model 4312, Cardiac Pacemakers, Inc.) were
implanted in the myocardium of the right ventricle and right
atrium, and the leads were attached to an unipolar multipro-
grammable pacemaker (model 8329, Medtronics, Inc.) posi-
tioned under the skin of the chest. Two ultrasonic time-transit
flow probes (model 2R or 3R Transonic Systems, Inc.) were
placed on the proximal left circumflex and anterior descending
coronary arteries. The wires and tubing were tunneled subcu-
taneously and brought out through the skin of the neck.
Data collection and calculation. Studies were performed
after full recovery from instrumentation (;2 weeks after the
initial operation), with the unsedated dogs lying on their right
sides and in a sling. The LV and LA catheters were connected
to pressure transducers (Statham P23DB) calibrated with a
mercury manometer. The signal from the micromanometer
was adjusted to match that of the catheters. The transit time of
5-MHz sound between the crystal pairs was determined and
converted to distance, assuming a constant velocity of sound in
blood of 1.55 m/ms. The analog signals were digitized with an
on-line analog-to-digital converter (Data Translation Devices)
at 200 Hz, using the SPECTRUM program (Wake Forest
University School of Medicine). Each data acquisition lasted
for 15 to 20 s, spanning several respiratory cycles. The deriv-
atives of LV pressure and volume were calculated using the
five-point Langrangian method (30).
Experimental protocol. Studies before CHF: effect of HOE-
140. We determined the effects of endogenous bradykinin by
using HOE-140. This agent is a potent, stable and specific
antagonist of the kinin beta2-receptor (11,31–33). We con-
firmed the adequacy of bradykinin blockade produced by the
dose of HOE-140 used in this study (0.3 mg/kg intravenously)
in a separate group of six conscious, instrumented animals
(14). Before HOE-140, the infusion of bradykinin (6 mg/kg plus
6 to 18 mg/kg per min intravenously) produced a decrease in
LV end-systolic pressure (Pes) (100 6 14 to 81 6 1 mm Hg, p ,
0.05) and significant (p , 0.05) increases in heart rate, stroke
volume (SV) and rate of LV relaxation, as well as improved LV
contractile performance. All of these hemodynamic effects of
bradykinin were completely blocked by pretreatment with
HOE-140 (0.3 mg/kg intravenously).
To obtain baseline values, data were initially recorded with
the study animals lying quietly on their sides without medica-
tion. Three sets of variably loaded pressure–volume loops were
generated by sudden, transient occlusion of the cavae. This
caused a progressive fall in LV end-systolic pressure and
volume over a 15-s recording period. Immediately after the
recording period, the caval occlusion was released and hemo-
dynamic variables were allowed to restabilize. After all vari-
ables returned to their baseline level, 0.3 mg/kg of HOE-140
was infused intravenously. The steady-state and transient caval
occlusion data were collected 5 to 10 min after the infusion
when a stable effect was present.
Studies during development of CHF. After completion of
the baseline studies, the pacing rate was adjusted, using the
external magnetic control unit, to 200 to 250 beats/min. Three
times per week the pacemaker rate was deactivated. The
animals were allowed to equilibrate for 30 min and then data
were collected. The pacing rate was returned to 200 to 250
beats/min. The pacing period lasted for 4 to 5 weeks. When the
LV end-diastolic pressure (Ped) during the nonpaced period
had increased by .15 mm Hg over the prepacing control level
and the animals had begun to show clear evidence of CHF
(anorexia, ascites and pulmonary congestion), the pacing was
discontinued and CHF data were obtained.
Studies after onset of CHF. The pacemaker was turned off
and the animals were allowed to stabilize for at least 30 min.
Data were recorded with the animals lying quietly on their
sides. Then the aforementioned protocols were repeated as
before CHF.
Data processing and analysis. To account for respiratory
changes in intrathoracic pressure, steady-state measurements
were averaged over a 15-s recording period that spanned
multiple respiratory cycles (29). The stored digitized data were
analyzed using the SPECTRUM program.
The LV volume was calculated as a modified general
ellipsoid using the equation VLV 5 (p/6)DAPDSLDLA, where
Abbreviations and Acronyms
CHF 5 congestive heart failure
dP/dt 5 rate of rise of left ventricular pressure
dV/dtmax 5 maximal rate of left ventricular filling
Ea 5 arterial elastance
LA 5 left atrial or atrium
LV 5 left ventricular or ventricle
Ped 5 left ventricular end-diastolic pressure
Pes 5 left ventricular end-systolic pressure
SV 5 stroke volume
TSR 5 total systemic resistance
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VLV 5 volume of LV; DAP 5 anterior-posterior LV dimen-
sion; DSL 5 septal-lateral LV dimension; and DLA 5 long-axis
LV dimension. This method of volume calculation gives a
consistent measure of LV volume despite changes in LV
loading conditions, chamber configuration and inotropic state
(34).
Stroke work was calculated by point-by-point integration of
the LV pressure–volume loop for each beat, as described by
Glower et al. (35). SV was calculated as LV end-diastolic
volume minus end-systolic volume. The rate of LV relaxation
was analyzed by determining the time constant of the iso-
volumic fall of LV pressure. LV pressure, from the time of
peak (2) rate of rise in LV pressure (dP/dt) until mitral
valve opening, was fit to an exponential equation P 5 PA exp
(2t/t), 1 PB, where P 5 LV pressure; t 5 time; and PA, PB and
t are constants determined by the data. Although the fall in
isovolumic pressure is not exactly exponential (36), the time
constant, derived from the exponential approximation, pro-
vides an index of the rate of LV relaxation (37). The total
systemic resistance (TSR) was estimated as Pes/cardiac output,
as suggested by Sunagawa et al. (38). The arterial elastance
(Ea) was calculated as Pes divided by SV.
Only caval occlusions that produced a fall in Pes of at least
30 mm Hg were analyzed. Premature beats and subsequent
beats were excluded from the analysis. The LV end-systolic
pressure and volume data during the fall in LV pressure,
produced by each caval occlusion, were fit using the least-
squares technique to
Pes 5 Ees ~Ves 2 V0,es!,
where Ees 5 slope of the linear end-systolic pressure–volume
relation, representing the LV end-systolic elastance; and
V0,es 5 intercept with the volume axis. The volume (V100)
associated with a Pes of 100 mm Hg was calculated as follows:
V100,es 5 V0,es 1 100/Ees.
The dP/dtmax–end-diastolic volume (Ved) and stroke work–
end-diastolic volume (SW 2 Ved) relations were quantitated
by fitting the data from the same beats from each caval
occlusion used to evaluate the Pes–Ves relation to
dP/dtmax 5 dE/dtmax~Ved 2 V0,dP/dt!,
where dE/dtmax 5 slope of the dP/dtmax–Ved relation, MSW 5
slope of the SW–Ved relation, and
SW 5 MSW~Ved 2 V0,SW!.
The positions of the dP/dtmax–Ved and SW–Ved relations
were calculated by determining the Ved associated with a dP/dt
of 1,000 mm Hg/s and SW of 1,000 mm Hg/ml:
V1,000,dP/dt 5 V0,dP/dt 1 1,000/~dE/dtmax!,
V1,000,SW 5 V0,SW 1 1,000/MSW
Plasma bradykinin determinations. The plasma bradyki-
nin levels were determined from arterial blood samples before
and after CHF. Ten milliliters of blood was withdrawn from
the LA catheter into a chilled preservative tube containing 5 ml
of an inhibitor mixture of aprotinin (10,000 kallikrein inhibitor
units per milliliter), phenanthroline (10 mg/ml), EDTA (20
mg/ml), trypsin inhibitor (0.8 mg/ml) and hexadimethrine
bromide (0.4 mg/ml). The samples were mixed with acetone
and immediately separated by centrifugation at 3,000 rpm for
10 min. Then a 5-ml plasma extract was transferred into a
tightly sealed, screw-capped polypropylene vial and stored
upright in dry ice. After labeling the vials, the specimens,
frozen in dry ice, were shipped to the Inter Science Institute.
Bradykinin was measured by the Inter Science Institute
using a radioimmunoassay kit according to the procedures
described by Jauch et al. (31) and Vavrek and Stewart (40),
with modifications made by the Inter Science Institute (41),
using a specific rabbit antibody directed against bradykinin-
bovine serum albumin. The specificity of the antibody pre-
cludes the necessity of further purification before the radioim-
munoassay test of specimens. The sensitivity of the assay,
determined as the least amount of bradykinin that can be
distinguished from zero, is 10 pg/ml. There is ,1% cross
reactivity with angiotensin I and II, arginine vasopressin and
endothelin. The interassay variabilities are 13%, 7% and 7.9%
at bradykinin levels of 38, 210 and 430 pg/ml, respectively. The
interassay variabilities are 16%, 8% and 9% at bradykinin
levels of 40, 220 and 420 pg/ml, respectively.
Statistical analysis. Variables of LV function were com-
pared before and after CHF, before and after drug use, using
the Student t test for paired observations and analysis of
variance with the Bonferroni correction for multiple-paired
comparisons, as appropriate. The slopes, volume–axis inter-
cepts and positions in the physiologic range of each of the
three relations for each condition were evaluated as the mean
values of the two or three caval occlusions performed under
each condition. Significance was accepted at p , 0.05. Steady-
state data were expressed as the mean value 6 SD; values for
LV pressure–volume relations were expressed as the mean
value 6 SE.
Postmortem evaluation. At the conclusion of the studies,
the animals were killed by lethal injection of sodium pentobar-
bital (100 mg/kg intravenously), and the hearts were examined
to confirm the proper instrumentation.
Results
Effects of pacing-induced CHF. The plasma bradykinin
concentration was 53.1 6 12.4 pg/ml before CHF and in-
creased to 234.2 6 19.4 pg/ml (p , 0.05) after CHF. Steady-
state measurements before and after CHF are summarized in
Table 1. LV pressure–volume analyses before and after CHF
are summarized in Table 2. After 4 to 5 weeks of rapid pacing,
Ped, LV end-systolic and end-diastolic volume, minimal LV
pressure, mean LA pressure, the time constant of LV relax-
ation (tau), TSR and Ea all significantly increased, whereas SV,
the peak rate of mitral flow (dV/dtmax), minimal LV pressure
and cardiac output were all significantly decreased.
After 4 to 5 weeks of rapid pacing, the slopes of the LV
end-systolic pressure–volume relation, the dP/dtmax–Ved rela-
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tion and the SW–Ved relation all significantly decreased and
were shifted toward the right, indicating a depression of LV
contractile performance. These observations are consistent
with our previous reports (9,42) demonstrating that long-term,
rapid pacing produces cardiac dilation, impairment of LV
systolic and diastolic function with clinical evidence of pulmo-
nary congestion and ascites.
Effect of HOE-140. The steady-state hemodynamic data
during control and HOE-140 infusion before and after CHF
are summarized in Table 1 and displayed in Figure 1. Before
CHF, HOE-140 caused no significant alterations in heart rate
(108 6 6 vs. 106 6 8 beats/min), Pes (102 6 12 vs. 103 6
13 mm Hg), TSR (0.068 6 0.013 vs. 0.070 6 0.013 mm Hg/ml
per min), mean LA pressure (5.5 6 3.4 vs. 5.7 6 3.3 mm Hg),
minimal LV pressure (0.5 6 3.4 vs. 0.6 6 3.6 mm Hg), tau
(25.5 6 3.0 vs. 26.1 6 4.1 ms) and dV/dtmax (222 6 35 vs. 219 6
47 ml/s). As shown in Figure 2, the contractile performance
measured by the slopes of the Pes–Ves (Ees) (6.8 6 0.6 vs. 6.7 6
0.6 mm Hg/ml, p 5 NS), dP/dtmax–end-diastolic volume (dE/
dtmax) (80.5 6 3.9 vs. 80.1 6 4.7 mm Hg/s per ml, p 5 NS) and
stroke work–Ved (MSW) (80.8 6 5.3 vs. 80.3 6 4.9 mm Hg,
p 5 NS) relations were also unaffected. However, with HOE-
140, coronary blood flow was significantly reduced (0.30 6 0.07
vs. 0.26 6 0.06 ml/beat, p , 0.05) due to the significant
increase in coronary vascular resistance.
After CHF (Tables 1 and 2, Fig. 1 and 3), HOE-140
exacerbated both the LV systolic and diastolic dysfunction
present with CHF. After CHF, HOE-140 produced a signifi-
Table 1. Effect of HOE-140 on Steady-State Hemodynamic Data Before and After Pacing-Induced
Congestive Heart Failure in Eight Dogs
Before CHF After CHF
Control HOE-140 Control HOE-140
Heart rate (beats/min) 108 6 6 106 6 8 115 6 9 120 6 18
Peak (1) dP/dt (mm Hg/s) 2,737 6 223 2,735 6 210 1,699 6 157† 1,678 6 189
Peak (2) dP/dt (mm Hg/s) 22,118 6 139 22,093 6 114 21,519 6 122† 21,501 6 129
LV end-diastolic pressure (mm Hg) 9.0 6 1.7 9.1 6 1.6 24.2 6 1.7† 29.1 6 2.7‡
LV end-systolic pressure (mm Hg) 102 6 12 103 6 13 98 6 8 104 6 7‡
Minimal LV pressure (mm Hg) 0.5 6 3.4 0.6 6 3.6 10.6 6 4.5† 12.9 6 2.8‡
Mean LA pressure (mm Hg) 5.5 6 3.4 5.7 6 3.3 17.9 6 5.1† 19.4 6 5.6‡
End-diastolic volume (ml) 40.4 6 7.0 40.7 6 6.8 50.2 6 5.1† 50.6 6 5.7
End-systolic volume (ml) 26.7 6 4.9 26.9 6 5.0 39.4 6 3.9† 40.8 6 3.7‡
Stroke volume (ml) 13.7 6 3.2 13.8 6 3.1 10.8 6 1.9† 9.8 6 2.0‡
Ea (mm Hg/ml) 7.5 6 1.1 7.6 6 1.6 10.5 6 2.2† 12.2 6 2.9‡
TSR (mm Hg/ml per min) 0.068 6 0.013 0.070 6 0.013 0.096 6 0.024† 0.110 6 0.032‡
Tau (ms) 25.5 6 3.0 26.1 6 4.1 43.5 6 3.1† 47.2 6 3.1‡
Maximal dV/dt (ml/s) 222 6 35 219 6 47 184 6 42 146 6 39
Mean coronary blood flow (ml/beat) 0.30 6 0.07 0.26 6 0.06* 0.31 6 0.16 0.27 6 0.14‡
*p , 0.05 compared with control value before CHF. †p , 0.05 compared with control value before CHF. ‡p , 0.05
compared with control value after CHF. Data are presented as mean value 6 SD. CHF 5 congestive heart failure;
dP/dt 5 rate of rise of left ventricular pressure; dV/dtmax 5 peak rate of mitral flow; Ea 5 arterial elastance; LA 5 left
atrial; LV 5 left ventricular; tau 5 time constant of LV relaxation; TSR 5 total systemic resistance.
Table 2. Effect of HOE-140 on the Pes–Ves, dP/dtmax–Ved and SW–Ved Relations Before and After Pacing-Induced Congestive Heart Failure
in Eight Dogs
Pes–Ves Relation dP/dtmax–Ved Relation SW–Ved Relation
Ees V0,es r V100,es dE/dtmax V0,dP/dt V1,000,dP/dt MSW V0,SW V1,000,SW
Before CHF
Control 6.8 6 0.6 10.2 6 1.9 0.994 6 0.01 25.4 6 2.0 80.5 6 3.9 6.4 6 0.8 19.0 6 1.3 80.8 6 5.3 20.1 6 1.6 32.8 6 1.6
HOE-140 6.7 6 0.6 10.1 6 2.3 0.981 6 0.01 25.6 6 2.0 80.1 6 4.7 6.2 6 3.4 18.9 6 3.6 80.3 6 4.9 20.0 6 1.8 32.6 6 1.6
After CHF
Control 5.3 6 0.7† 9.1 6 2.0 0.956 6 0.02 29.9 6 3.5* 51.2 6 2.7* 8.2 6 1.9 28.0 6 2.5* 59.6 6 2.6* 19.0 6 1.5 36.5 6 1.8*
HOE-140 4.6 6 0.5‡ 7.9 6 1.1‡ 0.975 6 0.01 32.6 6 3.0† 40.2 6 3.9† 5.5 6 2.4† 31.9 6 2.1† 47.5 6 2.5† 17.1 6 1.8† 38.8 6 2.8†
*p , 0.05 compared with control value before CHF. †p , 0.05 compared with control value after CHF. Data are presented as mean value 6 SE. dE/dtmax 5 slope
of dP/dtmax–Ved relation; Ees 5 slope of linear Pes–Ves relation; MSW 5 slope of stroke work–end-diastolic volume relation; Pes 5 end-systolic pressure; SW 5 stroke
work; Ved 5 end-diastolic volume, Ves 5 end-systolic volume; V0,es 5 intercept with volume axis; V100,es 5 volume associated with Pes of 100 mm Hg; V0,dP/dt 5
intercept with volume axis; V1,000,dP/dt 5 volume associated with dP/dt of 1,000 mm Hg/s; V0,SW 5 intercept with volume axis; V1,000,SW 5 volume associated with SW
of 1,000 mm Hg/ml.
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cant increase in Pes (98 6 8 vs. 104 6 7 mm Hg, p , 0.05), with
associated increases in TSR (0.096 6 0.024 vs. 0.110 6
0.032 mm Hg/ml per min, p , 0.05) and Ea (10.5 6 2.2 vs.
12.2 6 2.9 mm Hg/ml, p , 0.05), whereas the heart rate was
relatively unchanged. Tau was markedly prolonged (43.5 6 3.1
vs. 47.2 6 3.1 ms, p , 0.05), and dV/dtmax (184 6 42 vs. 146 6
39 ml/s, p , 0.05) was reduced due to an elevated minimal LV
pressure, despite an increase in mean LA pressure (17.9 6 5.1
vs. 19.4 6 5.6 mm Hg, p , 0.05). Furthermore, as demon-
strated in Figure 3, the slopes of LV pressure–volume relations
decreased: Ees (5.3 6 0.7 vs. 4.6 6 0.5 mm Hg/ml, p , 0.05),
dE/dtmax (51.2 6 2.7 vs. 40.2 6 3.9 mm Hg/s per ml, p , 0.05)
and MSW (59.6 6 2.6 vs. 47.5 6 2.5 mm Hg, p , 0.05). This
indicates depressed contractility.
Discussion
We found that plasma levels of bradykinin are elevated
fourfold in conscious animals with pacing-induced CHF. This
elevation of endogenous bradykinin stimulates B2-receptors,
producing both coronary and systemic arterial vasodilation and
improving LV relaxation, LV filling and LV contractile per-
formance. These data suggest that endogenous bradykinin may
help blunt the detrimental functional consequences of the
activation of other neurohormonal systems in CHF.
Measurements of normal plasma bradykinin levels have
varied owing to the short half-life of bradykinin in the blood
and its easy destruction during extraction procedures (23,43).
In the current study, we used the procedures described by
Jauch et al. (39), with modifications made by the Inter Science
Institute (41). Both destruction and activation of kinins were
arrested immediately in samples of blood, and the extraction
procedure allowed the active kinins to be concentrated. We
found plasma bradykinin levels of 53.1 6 12.4 pg/ml in normal
conscious dogs, similar to the measurements in normal humans
(39,44,45). After CHF, the plasma bradykinin levels increased
more than fourfold (234.2 6 19.4 pg/ml). The increase in
bradykinin with CHF was far higher than the intrasample and
intersample variability of the bradykinin assay. Furthermore,
the increase in bradykinin was not due to cross reactivity of the
assay with other neurohormones that are elevated in CHF. The
elevated plasma bradykinin in CHF may be due to cytokine
stimulation with CHF. In addition, aldosterone also triggers
Figure 1. An example of the effect of HOE-140 on LV pressure–
volume loops. Each loop was generated by averaging the data obtained
during a 15-s recording period, spanning several respiratory cycles.
Before CHF (left), the LV pressure–volume loops were relatively
unchanged after HOE-140. In contrast, after CHF (right), HOE-140
caused an increase in Pes and the pressure–volume loops were mark-
edly shifted upward.
Figure 2. Left ventricular pressure–volume relations determined from
one conscious dog before CHF. Before CHF, HOE-140 produced a
slight parallel rightward shift of the end-systolic pressure–volume
relation (top graph). Both the slopes and positions of dP/dtmax–end-
diastolic volume (bottom left graph) and stroke work–end-diastolic
volume (bottom right graph) relations were unchanged with HOE-
140, indicating that before CHF, blocking endogenous bradykinin with
HOE-140 had no inotropic effect on LV contractile performance.
Figure 3. Left ventricular pressure–volume relations determined from
the same conscious animal as in Figure 2 after CHF. After CHF,
HOE-140 produced rightward shifts of the end-systolic pressure–
volume, dP/dtmax–end-diastolic volume and stroke work–end-diastolic
volume relations, with decreased slopes. This indicates that blocking
endogenous bradykinin in CHF with HOE-140 caused decreased LV
contractile performance, which is in contrast to the effect of HOE-140
before CHF.
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kallikrein activation (20). Thus, the result of elevated circulat-
ing bradykinin in CHF may at least partially be stimulated by
activation of the renin-angiotensin system in CHF. It is also
possible that a decrease in bradykinin breakdown may also
contribute to the elevated bradykinin levels we observed in
CHF.
Bradykinin is a potent vasodilator. Consistent with previous
observations in normotensive rats (46) and normal humans
(11), we found that blocking endogenous bradykinin with
HOE-140 produced a reduction in coronary blood flow, with a
corresponding increase in coronary vascular resistance. We
also observed a similar response to HOE-140 in dogs with
CHF, suggesting that endogenous bradykinin plays a role in
the regulation of coronary circulation in both normal and CHF
states.
Although bradykinin has a potent vasodilatory effect, we
found that blocking the effect of the low level of bradykinin
(53.1 6 12.4 pg/ml) in normal animals had no detectable effect
on systolic pressure or systemic arterial resistance. This is
consistent with the observation in normal humans that the
threshold concentration of bradykinin to reduce arterial pres-
sure is at least 100 pg/ml (45). After CHF, the bradykinin level
in our animals was 234.2 6 19.4 pg/ml, far exceeding this
threshold. Blocking bradykinin B2-receptors after CHF in-
creased arterial pressure and resistance. These data imply that
endogenous bradykinin does not normally play a role in the
regulation of rest arterial blood pressure; however, after CHF,
the elevated bradykinin levels produced a vasodilatory effect
that partially offsets the vasoconstriction produced by activa-
tion of other neurohormonal systems.
The administration of exogenous bradykinin produces pos-
itive inotropic and lusitropic effects in the normal circulation
(14–16). Consistent with the lack of effect of the low levels of
bradykinin on systemic arterial resistance, we found that
bradykinin B2-receptor blockade had no effect on LV systolic
or diastolic performance before CHF. However, after CHF,
when bradykinin levels were elevated, HOE-140 produced a
further depression of LV contractile performance, a further
slowing of LV relaxation and a further increase in LV diastolic
and LA pressures. This indicates that the elevated levels of
bradykinin present in CHF help counteract the depressed LV
systolic and diastolic performance in CHF. The use of load-
insensitive measures of LV contractile performance demon-
strates that the decreased contractile performance demonstrates
that the decreased contractile function, when bradykinin ef-
fects are blocked in CHF, are not just due to increased arterial
resistance.
Our study did not address the mechanism of endogenous
bradykinin’s actions in CHF. The vasodilatory actions of brady-
kinin are mediated largely through the activation of bradykinin
B2-receptors that stimulated release of endothelium-derived
nitric oxide and prostacyclin (15,17,47–49). It is therefore
likely that the action of HOE-140 was to reduce the endoge-
nous bradykinin stimulated release of one or more of these
endothelium-derived vasodilators. The effect of bradykinin on
LV contractile performance may be partially mediated through
the B2-receptor–mediated inositol pathway that changes the
mobilization and reuptake of cytosolic Ca21 and alters myofi-
brillar Ca21 sensitivity (15,50–52). Bradykinin also activates
phospholipase adenyl cyclase and promotes intracellular alka-
lization by enhancing Na12H1 exchange through activation of
protein kinase C (52–54). Bradykinin may also potentiate the
release of catecholamines (16,55).
Study limitations. There are several methodologic issues
that should be considered in interpreting our data. First is the
experimental model of CHF. Although rapid pacing produces
an animal model of CHF that closely mimics the clinical
picture of congestive cardiomyopathy, we cannot be certain
our results apply to CHF that is due to other causes. Incessant
tachycardia does lead to clinical CHF in patients.
We studied the effect of acutely blocking the action of
bradykinin. It is possible that some of the biologic actions of
bradykinin may take weeks or months to reverse. These effects,
if any, cannot be determined from our study. However, our
study does demonstrate that blocking the effect of endogenous
bradykinin produces an acute hemodynamic response in CHF
that is different from the effect before CHF.
A third limitation is that we measured bradykinin levels in
arterial blood. Because bradykinin is inactivated by angiotensin-
converting enzyme, which exists in high levels in the pulmonary
circulation, venous levels of bradykinin may be higher than the
levels we measured in the arterial circulation. Further, local tissue
levels of bradykinin may also be higher than the circulating
arterial bradykinin level. However, these limitations did not
interfere with our assessment of the functional effects of endog-
enous bradykinin by blocking the bradykinin B2-receptor.
Angiotensin-converting enzyme inhibitors are beneficial in
patients with CHF (56). These effects have been attributed to
a reduction of neurohormonal activation by interfering with
the formation of angiotensin II. However, bradykinin inactiva-
tion is also blocked by angiotensin-converting enzyme inhibi-
tion (20). Our study suggests that the elevated endogenous
bradykinin level in CHF has a beneficial effect that partially
counterbalances the detrimental effects of angiotensin II in
CHF. Thus, some of the beneficial effects of angiotensin-
converting enzyme inhibition may be achieved by favorably
shifting the balance by both decreasing angiotensin II and
increasing bradykinin (17,57–59).
Conclusions. Levels of bradykinin found in normal con-
scious animals mildly increase coronary blood flow but do not
influence systemic arterial resistance or LV performance.
After CHF, the elevated endogenous bradykinin levels de-
crease systemic and coronary arterial resistance and enhance
LV contraction and relaxation. Thus, increased bradykinin
may partially offset the detrimental effects of activation of
other neurohormonal systems in CHF.
We acknowledge the computer programming of Ping Tan (SPECTRUM), the
technical assistance of Mack Williams and the secretarial assistance of Carol S.
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